10-Q quarterly report · filed Nov 3, 2026

Corcept Therapeutics Inc (CORT) Q3 2026 10-Q Quarterly Report

Short answer

Corcept Therapeutics Inc (CORT) filed its Q3 2026 10-Q quarterly report on Nov 3, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $340M (up 64.0% year over year) with net income of $127M.

Q3 2026 key financials · XBRL

Revenue
$340M
+64.0% YoY · +32.9% QoQ
Net income
$127M
+544.6% YoY · +194.9% QoQ
Operating margin
33.7%
EPS (diluted)
$1.04
+550.0% YoY · +166.7% QoQ

Source: XBRL data from the Corcept Therapeutics Inc (CORT) Q3 2026 10-Q on SEC EDGAR. USD.

Corcept Therapeutics Inc Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $340.5M, up 64.0% YoY from $207.6M, driven by Hypercortisolism Products and Lifyorli
  • Hypercortisolism Products revenue $249.1M, up from $207.6M; Lifyorli generated $91.4M after April launch
  • Cost-of-sales margin 98.6% vs 97.8% YoY, with cost of sales 1.4% vs 2.2% of revenue
  • Cash, equivalents and marketable securities $662.3M vs $532.4M; operating cash flow $159.7M vs $103.5M
  • 2026 outlook: R&D expense approximately unchanged; SG&A higher, IRA may reduce profits in 2026 and beyond

Risk Factors

  • New FDA relacorilant review risk: December 30, 2025 CRL triggered additional analyses and NDA resubmission
  • New regulatory risk: HHS re-examination of mifepristone safety announced September 2025
  • Competitive risk: Teva’s generic mifepristone materially reduced Hypercortisolism Product pricing
  • Operational concentration: Curant collects payments from insurers representing more than 99% of hypercortisolism revenue
  • Financial risk: OBBBA Medicaid funding cuts may increase patient-assistance costs and reduce product access

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Corcept Therapeutics Inc quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.